ClinicalTrials.gg
RecruitingNCT06245356TRIFLUOX-DPUpdated Dec 10, 2025

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

A Phase 2 interventional study of Lonsurf and Oxaliplatin in Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma and DPD Deficiency, sponsored by UNICANCER. Recruiting at 21 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by UNICANCER · Phase 2, Interventional, and Treatment

How we know · 14 judgments

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Planned enrollment
43rd of 88
73 · median 70
Started
2025
with 2 others
Phase 2
60 of 90
3 open now
Primary completion
2026-10
later than 5 of 11 live
Registered
85th of 90
by date
Lead sponsor
3 of 90
UNICANCER

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 43rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2025, is one of 60 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 85th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.

The main questions it aims to answer are:

  • Is this alternative chemotherapy option a better option in term of safety for this type of patients?
  • Does the combination of treatments improves the overall safety?
  • Does the combination of treatments improves the progression-free survival, overall survival, objective response rate and disease control rate?
  • Does the combination of treatment have an effect on quality of life?

Participants will:

  • Receive the trifluridine/tipiracil with oxaliplatin every 14 days, associated with:

    • Panitumumab or bevacizumab for colorectal adenocarcinomas
    • Nivolumab or trastuzumab for gastroesophageal adenocarcinomas.
  • Have a CT-Scan every 2 months until disease progression
  • Complete Health-related quality of life questionnaire every 2 months for a maximum of 6 months
  • Participate to the optional translational research: Blood samples fo DPYD genotyping and pharmacokinetic analysis
03

Conditions studied

  • Metastatic Colorectal Cancer
  • Metastatic Gastroesophageal Adenocarcinoma
  • DPD Deficiency

Keywords

  • Metastatic colorectal cancer
  • Metastatic Gastroesophageal Adenocarcinoma
  • DPD Deficiency
  • Trifluridine/Tipiracil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must have signed and dated a written form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
  2. Histological or cytological documentation of adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower oesophagus, gastroesophageal junction and gastric)
  3. Synchronous or metachronous colorectal or gastroesophageal cancer
  4. Presence of at least one according to v1.1
  5. No prior therapy for metastatic disease
  6. known DPD deficiency defined as plasma uracil concentration≥16 ng/ml For plasma uracil concentration [16-20[ ng/ml, plasma uracil dosage must be repeated in the 7 days to confirm that plasma uracil concentration ≥16 ng/ml. If the second result is different (i.e; uracil concentration \<16 ng/ml), keep the favourable result, and do not include the patient if only the first plasma uracil concentration≥16 ng/ml.
  7. Age ≥18 years
  8. (ECOG) performance status ≤1
  9. Adequate bone marrow, renal and liver functions as evidenced by the following laboratory requirements within 7 days prior to study treatment initiation:

    1. (ANC) ≥ 1,500/ mm³ without biologic response modifiers such as granulocyte colony-stimulating factor (G-CSF), within 21 days before the start of study treatment
    2. count ≥100,000/mm³, without platelet transfusion within 21 days before the start of study treatment
    3. (Hb) ≥9 g/dL, without blood transfusion or erythropoietin within 21 days before the start of study treatment
    4. Serum creatinine ≤1.5 x (ULN)
    5. as assessed by the estimated glomerular filtration rate (eGFR) ≥50 mL/min per 1.73 m² calculated by the Modification of Diet in Renal Disease (MDRD) abbreviated formula
    6. Total ≤ 1.5 x ULN
    7. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement of their cancer)
    8. Alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 5.0 x ULN for patients with liver involvement for their cancer and/or bone metastases)
    9. (INR) ≤1.5 or prothrombin time (PT) ≤1.5 x ULN Note: Patients on stable dose (dose has not been changed in at least 28 days) of anticoagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and INR / PT and PTT / aPTT test results are compatible with the acceptable benefit-risk ratio at the investigator's discretion. In such case, limits as noted would not apply
  10. For women of , negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test obtained within 7 days before the start of study treatment. Women not of reproductive potential are female patients who are or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy)
  11. For women of and men, agreement to use an adequate for the duration of study participation and up to 7 months following completion of therapy.
  12. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
  13. Affiliation to the Social Security System (or equivalent).

Exclusion criteria

Exclusion Criteria:

  1. Previous or concurrent cancer that is distinct in primary site or histology from colorectal or gastroesophageal cancer within 5 years prior to study inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non invasive tumor), Tis (carcinoma in situ) and T1 (lamina propria invasion)]
  2. Radiotherapy within 28 days prior to first dose of treatment
  3. Active cardiac disease including any of the following:

    1. Symptomatic Congestive heart failure ≥ (NYHA) class 3 or 4
    2. Severe Unstable angina (angina symptoms at rest)
    3. Myocardial infarction less than 12 months before first dose of treatment
  4. Uncontrolled hypertension (Systolic blood pressure ≥140 mmHg or diastolic pressure ≥ 90 mmHg) despite optimal medical management.
  5. Ongoing infection ≥Grade 2 ( v.5.0)
  6. Known history of (HIV) infection
  7. Chronic or C infection (if hepatitis status cannot be obtained from medical records, re-testing is required)
  8. Seizure disorder requiring medication
  9. Symptomatic brain or meningeal tumours
  10. History of organ allograft
  11. Known to any of the study drugs, study drug classes, or any constituent of the products
  12. In case of planned treatment with oxaliplatin: Peripheral neuropathy >Grade 1 (NCI CTCAE v.5.0)
  13. In case of planned treatment with bevacizumab: Major surgical procedure, open , or significant traumatic injury within 28 days prior to first dose of treatment
  14. In case of planned treatment with bevacizumab: Evidence or history of any bleeding diathesis, irrespective of severity. Any hemorrhage or bleeding event ≥CTCAE v 5.0 Grade 3 within 4 weeks prior to the start of study medication
  15. In case of planned treatment with trastuzumab or panitumumab or bevacizumab: Interstitial lung disease with ongoing signs and symptoms
  16. Inability to swallow oral medication
  17. Any uncontrolled malabsorption condition
  18. Pregnant or breast-feeding subjects. Women of must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of study drug
  19. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, substance abuse, medical or psychological reasons, or any condition that, in the opinion of the investigator, would interfere with the patient's participation in the study or evaluation of study treatment or interpretation of patient safety or study results
  20. Participation in another clinical study with an product during the last 30 days before inclusion
  21. Patients who might be interconnected with or dependent on the sponsor site or the investigator
  22. Persons deprived of their liberty or under protective custody or guardianship, or legal incapacity or limited legal capacity
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (estimated)

Study arms

  • Other
    Colorectal adenocarcinoma

    Trifluridine/tipiracil in association with oxaliplatin with or without: * Panitumumab in RAS wild type tumors * Bevacizumab in RAS wild type of right colon or RAS mutated tumors

    Drug: Lonsurf · Drug: Oxaliplatin · Drug: Panitumumab · Drug: Bevacizumab

  • Other
    Gastroesophageal adenocarcinoma

    Trifluridine/tipiracil in association with oxaliplatin with or without: * Trastuzumab in HER2-positive tumors (3+ IHC or 2+/FISH+) * Nivolumab if CPS≥5 and HER2-negative tumors

    Drug: Lonsurf · Drug: Oxaliplatin · Drug: Trastuzumab · Drug: Nivolumab

Interventions

  • DrugLonsurf

    Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)

  • Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)

  • Panitumumab intravenous injection 6 mg/kg (D1=D15)

  • Bevacizumab intravenous injection 5 mg/kg (D1=D15)

  • Trastuzumab intravenous injection 4 mg/kg (D1=D15)

  • Nivolumab intravenous injection 240 mg (D1=D15)

06

What researchers measure

Primary outcomes

  1. Treatment specific safety

    The percentage of patients without specific toxicities defined as grade 3-4-5 digestive toxicities (diarrhoea and/or stomatitis) and grade 4-5 neutropenia or febrile neutropenia over the first 2 cycles of first-line metastatic treatment. Toxicities will be graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5), widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: 1 month

Secondary outcomes

  1. Overall Safety

    All types of toxicities occuring during the study. The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout study completion, up to 2 years

  2. Compliance with study treatment

    Patients will record Trifluridine/tipiracil intake within a leaflet every day. Investigators will collect this data at every on site visit during the first 2 cycles (before Cycle 3).

    Time frame: 1 month

  3. Progression Free Survival

    The progression-free survival is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.

    Time frame: From baseline until disease progression or death, up to 2 years

  4. Overall Survival

    The overall survival is the length of time from baseline that patients enrolled in the study are still alive.

    Time frame: From baseline until disease progression or death, up to 2 years

  5. Objective response rate

    The objective response rate is defined as the percentage of patients with a complete response (CR) or a partial response (PR) for a given treatment.

    Time frame: From baseline until disease progression, up to 2 years

  6. Disease control rate

    The disease control rate is defined as the percentage of patients with a CR, a PR or stable disease for a given treatment.

    Time frame: From baseline until disease progression, up to 2 years

  7. Quality of life questionnaire - Core 30 (QLQ-C30)

    Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At baseline, 2 months, 4 months, and 6 months

  8. Quality of life questionnaire - Oesophago-Gastric (QLQ-OG25)

    This EORTC oesophago-gastric cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-OG25 contains 25 items organized into six scales: dysphagia (three items), eating restrictions (four items), reflux (two items), odynophagia (two items), pain and discomfort (two items) and anxiety (two items), and ten single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.

    Time frame: At baseline, 2 months, 4 months, and 6 months

  9. Quality of life questionnaire - Colorectal (QLQ-CR29)

    This EORTC colorectal cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-CR29 has 5 functional and 18 symptom scales. It contains 29 items organized into four subscales: urinary frequency (two items), blood and mucus in stool (two items), stool frequency (two items), and body image (three items), and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest, impotence, sexual interest, and dyspareunia). All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.

    Time frame: At baseline, 2 months, 4 months, and 6 months

07

Study locations

3 of 21 sites recruiting
  • CHU Amiens
    Amiens, 80054, France
    Not yet recruiting
    • Vincent HAUTEFEUILLE, MD · Contact
  • Institut de Cancérologie de l'Ouest
    Angers, 49055, France
    Not yet recruiting
    • Victor SIMMET, MD · Contact
  • Institut du Cancer d'Avignon
    Avignon, 84918, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Jean Minjoz
    Besançon, 25000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier de Cholet
    Cholet, 49300, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Georges François Leclerc
    Dijon, 21079, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hôpital Privé Jean Mermoz
    Lyon, 69008, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Régional du Cancer de Montpellier - ICM Val d'Aurelle
    Montpellier, 34298, France
    Recruiting
    • Emmanuelle SAMALIN, MD · Contact
  • Hôpital Saint Louis
    Paris, 75010, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Saint Antoine
    Paris, 75012, France
    Recruiting
    • Daniel LOPEZ, MD · Contact
  • Hôpital Cochin
    Paris, 75014, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital des Diaconesses Croix Saint Simon
    Paris, 75960, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospices Civils de Lyon
    Pierre-Bénite, 69495, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU de Poitiers
    Poitiers, 86000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU de REIMS
    Reims, 51092, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Godinot
    Reims, 51100, France
    Recruiting
    • Damien BOTSEN, MD · Contact
  • Institut de Cancérologie de l'Ouest - Site René Gauducheau
    Saint-Herblain, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • CHU Saint-Etienne
    Saint-Priest-en-Jarez, 42270, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CH de Saint-Malo
    St-Malo, 35403, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Nord Franche-Comté / Site du Mittan
    Trévenans, 90400, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, 54519, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 19 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 7, 2024
StartActual
Mar 21, 2025
Primary completionEst.
Oct 22, 2026
CompletionEst.
Oct 21, 2028
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06245356
Lead sponsor
UNICANCER
Collaborators
Servier
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Mar 21, 2025
Primary completion
Oct 22, 2026 (estimated)
Completion
Oct 21, 2028 (estimated)
Last update
Dec 10, 2025

Study contacts

Emilie BRUMENT
Contact
e-brument@unicancer.fr
+33(0)6 68 32 03 59
Emmanuelle SAMALIN, MD
principal investigator · Institut du Cancer de Montepllier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · Bevacizumab

Start the discussion